- freely available
Viruses 2013, 5(4), 1143-1152; doi:10.3390/v5041143
Published: 23 April 2013
Abstract: Human Immunodeficiency Virus type 1 (HIV-1) is a retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV-1 Tat protein upregulates transcriptional transactivation. The nucleocapsid protein NC of HIV-1 is a component of virion and plays a key role in genome packaging. Herein, we have demonstrated the interaction between NC and Tat by means of a yeast two-hybrid assay, GST pull-down analysis, co-immunoprecipitation and subcellular colocalization analysis. We observed that the level of Tat was significantly reduced in the presence of NC. But NC did not affect mRNA expression level of Tat. The level of Tat in the presence of NC was increased by treating cells with a proteasome inhibitor, MG132. The ubiquitination state of Tat was not seen to increase in the presence of NC, suggesting the proteasomal degradation was independent of ubiquitination. Lowered level of Tat in the presence of NC led to a decrease in Tat-mediated transcriptional transactivation.
It is estimated that there are 39 million AIDS patients worldwide. After 8–10 years of asymptomatic period, HIV causes devastation of the immune system leading to immunodeficiency. The virus infects immune cells including CD4+ T cells, dendritic cells and macrophages .
HIV Tat is a small nuclear protein encoded by an RNA consisting of two exons produced from multiple splicing . It binds to the transcription activator response (TAR) element located at the 5' end of the viral RNA transcript and enhances transcription activity . TAR RNA possesses a secondary structure consisting of a stem, bulge and loop, of which the bulge is the site where Tat binds . It recruits human cyclinT1-Cdk 9 complex which is the component of a positive transcription elongation factor b (P-TEFb), to the loop . Cdk 9 induces hyperphosphorylation of RNA polymerase II, resulting in enhanced transcription elongation. Tat also recruits p300/CBP and PCAF which are transcriptional coactivators/acetyltransferases to the promoter [4,5,6]. P-TEFb is then readily recruited to the promoter by acetylated Tat.
Nucleocapsid (NC) is a 55 amino-acid basic protein produced from the processing of Gag precursor. It is a zinc finger protein containing two copies of CCHC motifs that is conserved among retroviruses . This domain binds to the packaging signal (psi) at 5' LTR of the viral genomic RNA for encapsidation [8,9,10]. It possesses a nucleic acid chaperone activity which is crucial for the annealing of tRNA3Lys and plus strand transfer . It also plays a role in minus strand transfer by destabilization of TAR and the pausing of reverse transcription . Another activity of NC is the induction of dimerization of viral genomic RNA in the virion core . Virion NC was also shown to migrate from cytoplasm to nucleus and to control early viral mRNA . Thus NC plays multiple roles in virus life cycle.
The 55 KDa Gag precursor protein expressed from unspliced viral mRNA is transported to plasma membrane. After budding, Gag is cleaved by viral protease to produce p17 matrix, p24 capsid, p7 nucleocapsid, and p6 .
Herein is reported an additional role of NC based on the novel observation that NC and Tat interacted with each other. We hypothesize that NC from prematurely processed Gag may control transcriptional activation by Tat at a late stage of viral infection.
2. Results and Discussion
Plasmid expressing NC and plasmid expressing Tat were cotransformed to yeast strain AH109 and the interaction of the two proteins were observed (Figure 1A). To confirm specific interaction between NC and Tat, HIV-1 Vpu protein was used as a negative control. Yeast cell cotransformed with NC and Vpu didn’t grow in SD media D.O. tryptophan, leucine, and histidine. Next, in vitro pulldown assay was performed. Purified recombinant GST-fused NC or GST alone was mixed with cell lysates of BHK-21 expressing Tat. The binding of Tat to GST-fused NC, not to GST, was observed (Figure 1B). GST pulldown of Tat was visualized by western blot. Coimmunoprecipitation was also used for observing the interaction between the two proteins. From the cell lysate expressing NC and Tat, the two proteins were immunoprecipitated together (Figure 1C). But, NC and Vpu proteins were not observed to interact with each other. Subcellular colocalization of the two proteins was also confirmed under laser scanning confocal microscope. It has been reported that virion NC localizes to the nucleus at the early infection stage . In our experiments, NC was predominantly observed in the cytoplasm in the absence of Tat. It seemed that only part of overexpressed NC translocated to nucleus in the absence of Tat. However, in the presence of Tat, NC was shown to translocate to the nucleus and colocalize with Tat (Figure 1D). Both NC and Tat are translated in the cytoplasm and the binding between the two proteins seems to recruit NC to nucleus with their specific interaction. Tat has a nuclear localization signal (NLS) in the basic domain and mainly localizes in the nucleus, inducing transcription activation. The binding between the two proteins resulted in translocation of NC to the nucleus.
The outcome of interaction between the two proteins was explored. When the two proteins were co-expressed in HEK293 cells, the amount of Tat was observed to decrease through a western blot analysis (Figure 2A). Co-expression of GST did not alter the amount of Tat. To determine whether this change resulted from transcriptional control, we examined the amount of mRNA expressing Tat by reverse transcription PCR analysis. The amount of mRNA expressing Tat did not change in the presence or in the absence of NC (Figure 2B). Accordingly, Tat was hypothesized to degrade posttranslationally in the presence of NC. The primary degradation mechanism of proteins in eukaryotic cells involves the ubiquitin-proteasome pathway. Ubiquitin binds to unnecessary or misfolded proteins and this modification is recognized by the 26s proteasome leading to degradation of the target proteins . To confirm whether the decrease of Tat in the presence of NC was via proteasomal degradation, MG132, a proteasome inhibitor, was used. The amount of Tat was seen to decrease less in the presence of NC when the cells were treated with MG132 (lanes 2 and 5, Figure 2C). As a comparison, the amount of Tat did not decrease in the presence of HCV core (lanes 3 and 6). The proteasome constitutively degrades nearly all proteins, so treatment with MG-132 is expected to increase the amount of Tat in the cell, appearing as if there was an increase in Tat expression. However, this is actually a decrease in Tat degradation. There is a decrease in Tat level with NC, but not alone or with HCV core protein, in untreated cells. This difference is alleviated when the proteasome is shut down, thus the proteasome is most likely causing the induced degradation of Tat by NC. To see whether ubiquitination occurred before the proteasomal degradation of Tat, ubiquitination assay was performed. In the presence of NC, the ubiquitination of Tat did not increase (Figure 2D). Hdm2, a proto-oncoprotein, is already known to induce the ubiquitination of Tat  and this was therefore used as the positive control in this experiment.
Since Tat binds to the TAR RNA element and activates transcription elongation , we checked whether the degradation of Tat by NC affected this process. A reporter plasmid containing the luciferase gene under the control of HIV-1 LTR promoter was used. As negative controls, HIV p24, or GST was used instead of NC. In the presence of Tat, reporter activity increased notably (Figure 3A). In the presence of NC, reporter activity decreased 22% when compared to the tests in the presence of HIV p24 or GST. The decreased reporter activity by NC was effectively rescued by treatment with MG132 (Figure 3B). Thus, we have confirmed that the NC-mediated degradation of Tat results in the decrease of transcriptional activation.
There has been a report that HIV Tat is degraded by cellular p14ARF in an ubiquitin-independent pathway . In the latter study the degradation resulted in a decrease of transactivation. Many other investigations have reported that proteasomal degradation occurs independently of ubiquitination . For example, tumor suppressor p53 is degraded by both the ubiquitin-dependent and ubiquitin-independent pathways . There is also a report of viral transactivator degradation by its own viral protein. The hepatitis B virus transactivator X protein is degraded by both ubiquitin-dependent and ubiquitin-independent pathways . Proteasomal degradation of HBV X protein induced by HBV core was suggested as a new mechanism of controlling virus life cycle .
Tat upregulates transcription from proviral genome. Transcribed early genes include Tat, Rev, and Nef. Late genes include Gag, Pol, Env, Vpr, Vpu, and Vif which are expressed in a Rev-dependent manner [22,23]. Although cleaved NC is generally found after proteolytic processing of Gag in released viral particles, premature processing of HIV Gag in cytoplasm is also reported . A similar premature cytoplasmic processing of Gag was also shown in an avian retrovirus . When NC is accumulated after premature processing in cytoplasm, it would have a chance to interact with Tat which was abundantly expressed at the early stage of infection. This interaction can lead to degradation of Tat via proteasomal pathway, leading to decrease in transcription at late stage of viral infection cycle. The 22% decrease of Tat-mediated transcription in the presence of NC in our experiment cannot be responsible for the entire silencing of transcription at the late stage. Since both NC and Tat were overexpressed in our experiment, Tat degradation effect would not be fully reflected. And there could be other mechanisms yet to be elucidated responsible for this transcriptional control. Nonetheless, the virus needs to minimize unnecessary transcription from the viral genome.
Based on our findings, we suggest an additional role of NC related to transcriptional control at the late stage of HIV replication.
3.1. Reporter Assay
For the transcription activity tests, BHK21 or HEK293 cells were used. Plasmids pcDNA/luc-LTR (0.5 μg), pBud-Tat/NC (2 μg), pBud-Tat/p24 (2 μg), pBud-Tat/GST (2 μg), and pCH110 (0.5 μg, Amersham Biosciences) were mixed with 8 μg of Lipofectamin 2000 (Invitrogen) and cells were incubated. After 19 h, MG132 (Calbiochem) was added at 10 μM to the mixture and incubated for 5 h. Luciferase assay mixture (Promega) was added and the activity was measured in a luminometer (Perkin Elmer).
3.2. Proteasomal Degradation Assay
Cells were seeded in a 60 mm plate at 2 × 105 cells and incubated for 18 h. Then 2 μg of pcDNA/V5-Tat, 0.5 μg of pCMV/Flag-NC and 0.5 μg of pcDNA-GST (or pcDNA-HA-core) were transfected to the cells using Lipofectamin 2000. After 18 h of incubation, 10 μM of MG132 (Calbiochem) was added to the mixture and incubated for a further 6 h.
3.3. Yeast Two Hybrid Assay
The Matchmaker two-hybrid system 3 (Clontech) was used. Plasmids pGBK-NC, pGAD-Tat and pGAD-Vpu were constructed and utilized according to the manufacturer’s protocol. pGBKT7-53 (murine p53) and pGADT7-T (SV40 large T antigen) were used as positive controls. Yeast strain AH109, trasformed only with pGAD-Tat or pGAD-Vpu were used as negative controls.
3.4. GST Pulldown
To obtain NC fused to GST, 1 liter of E. coli harboring pGNC1 was cultured and induced with 1 mM IPTG for 3 h. The protein was purified using affinity chromatography.
For GST pulldown analysis, 10 μg of pcDNA/V5-Tat was transfected to 5 × 105 BHK-21 cells. After 24 h, a RIPA lysis buffer (50 mM Tris-Cl, pH 8.0, 1% NP-40, 0.5% sodium deoxycholate, and 150 mM NaCl) was added and lysis was performed at 4 °C for 30 min. The pellet was discarded after centrifugation and the lysate was obtained. Exactly 4 μg each of GST and GST-NC and 30 μL of glutathione sepharose 4B bead (Amersham Biosciences) were added to the lysate and the mixture was incubated at 4 °C overnight. Exactly 1 mL of HNGT buffer was used for washing and bound proteins were eluted after boiling with a 4×SDS sample buffer.
Exactly 8 μg of pcDNA/V5-Tat or pcDNA/V5-Vpu and 2 μg of pCMV/Flag-NC were used for transfection of HEK293 cells. Cells were lysed with a RIPA buffer in 24 h and anti-Flag antibody was added and further incubated at 4 °C overnight. Exactly 20 μL of protein G (Sigma-Aldrich) was added and the mixture was washed with lysis buffer 3 times.
3.6. Subcellular Colocalization Analysis
Plasmids pcDNA/V5-Tat and pCMV/Flag-NC were used to transfect HEK293 cells. Cells were fixed and rabbit polyclonal anti-Flag antibody was added and incubated for 1 h. After washing 3 times, FITC-conjugated secondary antibody was added and the mixture was then incubated for 1 h. After washing 3 times, 1:200 diluted mouse monoclonal anti-V5 antibody was added. After 3 times of washing, TRITC-conjugated secondary antibody was incubated and the mixture was mounted on a glass plate and observed under a confocal scanning laser microscope (Zeiss).
3.7. Realtime RT PCR
Plasmids pcDNA/V5-Tat and pCMV/Flag-NC or pcDNA/HA-Core, pcDNA/HA-Rev were used for transfection of HEK293 cells. Cells were harvested after 24 h and total RNA was isolated using an RNA kit (Macherey-Nagel). Reverse transcription was performed using M-MLV reverse transcriptase (United States Biological) with the primer 5'-CTATTCCTTCGGGCCTGT-3'. Real-time PCR was performed with iQ SYBR Green supermix (Bio-Rad) for Tat and GAPDH gene expression. The real-time detection system was used to monitor the SYBR green signal at the end of each expression period for 40 cycles. Tat RNA levels were calculated by the delta/delta CT method with GAPDH genes.
3.8. Ubiquitination Assay
Exactly 7 μg of pcDNA/HA-Tat, 2 μg of pCMV/Flag-NC and 5 μg of His-ubiquitin were used for the transient transfection of HEK293 cells. 40 hours after transfection, MG132 was added at 10 mM and the mixture was incubated for 5 h. Cells were then lysed with 1×RIPA buffer and subjected to sonication for 5 min. Supernatant was collected after centrifugation and loaded on Ni-NTA resin (Qiagen). After 5 h of binding reaction, the column was washed with 1×RIPA buffer 3 times and the eluate was analysed on an SDS-PAGE.
We showed the interaction between NC and Tat. The interaction induced nuclear translocation of NC and degradation of Tat via proteasomal pathway. Accumulation of prematurely processed NC in the cytoplasm can lead to decrease of Tat-mediated transcription.
We would like to thank Steven R. Grossman for providing the pCMV-mdm2, Ji Chang You for pCMV/Flag-NC and pGNC1 plasmids, and Yonghoon Kee for plasmid expressing Ubiquitin. This work was supported by 2008 National Research Foundation of Korea Grant (C00195) funded by the Korean Government and 2012 GRRC.
Conflict of Interest
The authors declare no conflict of interest.
References and Notes
- Kim, S.Y.; Byrn, R.; Groopman, J.; Baltimore, D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: Evidence for differential gene expression. J. Virol. 1989, 63, 3708–3713.
- Marcello, A.; Zoppe, M.; Giacca, M. Multiple modes of transcriptional regulation by the HIV-1 Tat transactivator. IUBMB Life 2001, 51, 175–181, doi:10.1080/152165401753544241.
- Raha, T.; Cheng, S.W.; Green, M.R. HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol. 2005, 3, e44, doi:10.1371/journal.pbio.0030044.
- Hottiger, M.O.; Nabel, G.J. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J. Virol. 1998, 72, 8252–8256.
- Marzio, G.; Tyagi, M.; Gutierrez, M.I.; Giacca, M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. USA 1998, 95, 13519–13524.
- Ping, Y.H.; Rana, T.M. Tat-associated kinase (P-TEFb): A component of transcription preinitiation and elongation complexes. J. Biol. Chem. 1999, 274, 7399–7404, doi:10.1074/jbc.274.11.7399.
- Covey, S.N. Amino acid sequence homology in gag region of reverse transcribing elements and the coat protein gene of cauliflower mosaic virus. Nucleic Acids Res. 1986, 14, 623–633, doi:10.1093/nar/14.2.623.
- Dannull, J.; Surovoy, A.; Jung, G.; Moelling, K. Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J. 1994, 13, 1525–1533.
- Clever, J.; Sassetti, C.; Parslow, T.G. RNA secondary structure and binding sites for gag gene products in the 5' packaging signal of human immunodeficiency virus type 1. J. Virol. 1995, 69, 2101–2109.
- Zhang, Y.; Barklis, E. Nucleocapsid protein effects on the specificity of retrovirus RNA encapsidation. J. Virol. 1995, 69, 5716–5722.
- Druillennec, S.; Caneparo, A.; de Rocquigny, H.; Roques, B.P. Evidence of interactions between the nucleocapsid protein NCp7 and the reverse transcriptase of HIV-1. J. Biol. Chem. 1999, 274, 11283–11288, doi:10.1074/jbc.274.16.11283.
- Cimarelli, A.; Sandin, S.; Hoglund, S.; Luban, J. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J. Virol. 2000, 74, 3046–3057, doi:10.1128/JVI.74.7.3046-3057.2000.
- Zhang, J.; Crumpacker, C.S. Human immunodeficiency virus type 1 nucleocapsid protein nuclear localization mediates early viral mRNA expression. J. Virol. 2002, 76, 10444–10454, doi:10.1128/JVI.76.20.10444-10454.2002.
- Gottlinger, H.G.; Sodroski, J.G.; Haseltine, W.A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1989, 86, 5781–5785, doi:10.1073/pnas.86.15.5781.
- Ciechanover, A.; Orian, A.; Schwartz, A.L. Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays 2000, 22, 442–451, doi:10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q.
- Bres, V.; Kiernan, R.E.; Linares, L.K.; Chable-Bessia, C.; Plechakova, O.; Treand, C.; Emiliani, S.; Peloponese, J.M.; Jeang, K.T.; Coux, O.; et al. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat. Cell Biol. 2003, 5, 754–761, doi:10.1038/ncb1023.
- Gargano, B.; Fiorillo, M.; Amente, S.; Majello, B.; Lania, L. p14ARF is capable of promoting HIV-1 tat degradation. Cell Cycle 2008, 7, 1433–1439, doi:10.4161/cc.7.10.5878.
- Orlowski, M.; Wilk, S. Ubiquitin-independent proteolytic functions of the proteasome. Arch. Biochem. Biophys. 2003, 415, 1–5, doi:10.1016/S0003-9861(03)00197-8.
- Asher, G.; Lotem, J.; Sachs, L.; Kahana, C.; Shaul, Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. USA 2002, 99, 13125–13130, doi:10.1073/pnas.202480499.
- Kim, J.H.; Sohn, S.Y.; Yen, T.S.; Ahn, B.Y. Ubiquitin-dependent and -independent proteasomal degradation of hepatitis B virus X protein. Biochem. Biophys. Res. Commun. 2008, 366, 1036–1042, doi:10.1016/j.bbrc.2007.12.070.
- Kim, J.H.; Kang, S.; Kim, J.; Ahn, B.Y. Hepatitis B virus core protein stimulates the proteasome-mediated degradation of viral X protein. J. Virol. 2003, 77, 7166–7173, doi:10.1128/JVI.77.13.7166-7173.2003.
- Kingsman, SM.; Kingsman, KA. The regulation of human immunodeficiency virus type-1 gene expression. Eur. J. Biochem. 1996, 240, 491–507.
- Mann, D.A.; Mikaelian, I.; Zemmel, R.W.; Green, S.M.; Lowe, A.D.; Kimura, T.; Singh, M.; Butler, P.J.; Gait, M.J.; Karn, J. A molecular rheostat: Co-operative rev binding to stem I of the Rev-response element modulates human immunodeficiency virus type-1 late gene expression. J. Mol. Biol. 1994, 241, 193–207, doi:10.1006/jmbi.1994.1488.
- Kaplan, A.H.; Swanstrom, R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc. Natl. Acad. Sci. USA 1991, 88, 4528–4532, doi:10.1073/pnas.88.10.4528.
- Burstein, H.; Bizub, D.; Skalka, A.M. Assembly and processing of avian retroviral Gag polyproteins containing linked protease dimers. J. Virol. 1991, 65, 6165–6172.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).